David Mack is an Associate Professor in the Departments of Rehabilitation Medicine, Bioengineering, and Physiology and Biophysics, as well as an Investigator in the Institute for Stem Cell and Regenerative Medicine at the University of Washington. David is a geneticist and developmental biologist by training and his laboratory has a longstanding interest in how stem cells make fate decisions during embryonic development by coordinating their intrinsic genetic program with cues from their surrounding microenvironment. The goal of the Neuromuscular Disease Research Group (NDRG) that David directs, is to create stem cell models of neuromuscular diseases (NMDs) to identify the molecular drivers of pathology and then use these models for drug discovery and validation. The NDRG is responsible for creating the iPSC lines for various NMDs that are part of Kinea Bio’s drug development pipeline and working closely with Curi Bio to develop the Mantarray™ platform to measure functional recovery after AAV-mediated gene transfer interventions. David worked for more than a decade with Casey Childers on IND-enabling studies in the canine model of X-linked myotbubular myopathy. Their work showed that AAV8-mediated gene transfer restores muscle strength to normal levels and lasts for at least a decade. David Mack is a co-founder of Kinea Bio.